Inspire Pharmaceuticals Licenses Novel Glaucoma Technology; Addition of New Ophthalmic Program Enhances Pipeline
Business Wire - November 4, 2004
DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced an agreement to license exclusively several patents from the Wisconsin Alumni Research Foundation (WARF) for use in developing and commercializing new therapeutics for tr... (Read More)
Minnesota Optometric Association Recommends Early Detection of Diabetes with Annual Eye Exams; November is American Diabetes Month
Business Wire - November 4, 2004
MINNEAPOLIS -- Diabetes is the leading cause of blindness among people aged 20-74 in Minnesota. Each year, according to the Minnesota Department of Health (MDH), between 400 and 700 Minnesotans go blind due to diabetes complications. Even when blo... (Read More)
Don't be blind-sighted by glaucoma; the best defense against glaucoma is through early detection and treatment
Saturday Evening Post - November 1, 2004, by Patrick Perry
An interview with Dr. Darrell WuDunn
The number one cause of preventable blindness, glaucoma was once inextricably linked to increased intraocular pressure (IOP). Pioneers in glaucoma research, however, disproved the assumption, after discoverin... (Read More)
TargeGen, Inc. Appoints Charles P. Theuer, M.D., Ph.D. to Position of Vice President, Clinical Research and Chief Medical Officer
PR Newswire - October 26, 2004
SAN DIEGO, Oct. 26 /PRNewswire/ -- TargeGen, Inc., a biotechnology company focusing on small molecule kinase inhibitors for the treatment of ischemic disease, cancer, and eye disease today announced the appointment of Charles P. Theuer to the pos... (Read More)
Alcon Commits $1.125 Million to EyeCare America's Seniors EyeCare Program; National, Award-Winning Program Provides Eye Exams and Treatment at No Cost
PR Newswire - October 26, 2004
SAN FRANCISCO, Oct. 26 /PRNewswire/ -- EyeCare America, the public service program of the Foundation of the American Academy of Ophthalmology (FAAO), announced today that it has been awarded a $1.125 million grant from Alcon. The five-year unrest... (Read More)
Latest Emerging and Disruptive Market Analysis from Life Science Insights Forecasts the Therapeutic RNAi Market
Business Wire - October 20, 2004
FRAMINGHAM, Mass. -- Leading independent research and advisory firm Life Science Insights, an IDC Company, has published an analysis of the emerging therapeutic RNAi market. Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis examines the t... (Read More)
TargeGen TG100-115 is Named One of Three Finalists for UCSD CONNECT 2004 Most Innovative Product Award in Biotechnology R&D Category
PR Newswire - October 19, 2004
SAN DIEGO, Oct. 19 /PRNewswire/ -- TargeGen, Inc., a biopharmaceutical company focusing on edema, cardiovascular (ischemic) diseases, cancer and eye disease, today announced that the Company has been named as one of three finalists for the UCSD 2... (Read More)
Bascom Palmer Eye Institute Broadens Growing Network of Clinical Leaders Offering NovaVision VRT
Business Wire - October 18, 2004
BOCA RATON, Fla. -- Top-Rated U.S. Eye Hospital Now Offering Revolutionary Treatment That Restores Vision Loss Caused by Stroke or Brain Trauma
NovaVision, Inc. today announced that the University of Miami's Bascom Palmer Eye Institute, one of t... (Read More)
FedEx Doubles Flights to China Increasing Market Leadership; 23 Weekly Flights Increase Opportunities for International Customers; China Exports up 52
Business Wire - October 18, 2004
MEMPHIS, Tenn. -- FedEx Express, an operating unit of FedEx Corp. (NYSE:FDX), was today awarded 12 additional weekly flights to China by the U.S. Department of Transportation, bringing its total to 23. The additional authority will allow FedEx Exp... (Read More)
Bausch & Lomb Introduces Easy-to-Swallow PreserVision Soft Gels
Business Wire - October 7, 2004
ROCHESTER, N.Y. -- Bausch & Lomb (NYSE:BOL):
--Available in Original AREDS Formula and a Lutein Formula for Eye Health
--AREDS Formula Only Clinically Proven Eye Vitamin to Reduce Risk of Vision Loss in Age-related Macular Degeneration
B... (Read More)
Miravant Announces PHOTREX as New Brand Name For SnET2 PDT
Business Wire - October 6, 2004
SANTA BARBARA, Calif. -- Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in photodynamic therapy (PDT), today announced PHOTREX(TM) as the new brand name for SnET2, a proposed PDT drug for the treatmen... (Read More)
Hypertension: management in adults with diabetes
Diabetes Forecast - October 1, 2004, by Shauna S. Roberts
The America. Diabetes Association regularly develops and updates guidelines for doctors for treating diabetes. Each month, one of these clinical practice guidelines will be discussed, to provide you with an inside look at all the latest ADA recomm... (Read More)
|
